SABCS 2023 | HER2-enriched breast cancer: TP53 mutations and response to aromatase inhibitors

Maggie Chon U Cheang, MD, PhD, Institute of Cancer Research, London, U, tells us more about an unexpected finding in Phase III POETIC trial (NCT02338310) where an intriguing paradox was noted in HER2-enriched breast cancer where TP53 mutations, which are generally associated with a poor response, showed an association with a good early response to aromatase inhibitors. Dr Cheang explains more about these findings and the potential implications. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.